22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis... Show more
XXII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 40 cases where XXII's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XXII just turned positive on July 07, 2025. Looking at past instances where XXII's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where XXII advanced for three days, in of 223 cases, the price rose further within the following month. The odds of a continued upward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XXII declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for XXII entered a downward trend on July 11, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XXII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.586) is normal, around the industry mean (4.131). XXII has a moderately low P/E Ratio (0.005) as compared to the industry average of (20.434). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.003). XXII has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.052). P/S Ratio (0.044) is also within normal values, averaging (2.136).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XXII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 68, placing this stock worse than average.
a plant biotechnology company
Industry Tobacco
A.I.dvisor tells us that XXII and UVV have been poorly correlated (+16% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XXII and UVV's prices will move in lockstep.
Ticker / NAME | Correlation To XXII | 1D Price Change % | ||
---|---|---|---|---|
XXII | 100% | -9.12% | ||
UVV - XXII | 16% Poorly correlated | -0.15% | ||
TPB - XXII | 13% Poorly correlated | -0.56% | ||
RLX - XXII | 12% Poorly correlated | +0.44% | ||
MO - XXII | 9% Poorly correlated | -1.28% | ||
KAVL - XXII | 7% Poorly correlated | +0.75% | ||
More |
Ticker / NAME | Correlation To XXII | 1D Price Change % |
---|---|---|
XXII | 100% | -9.12% |
Tobacco industry (26 stocks) | 67% Closely correlated | -0.25% |
miscellaneous industry (29 stocks) | 45% Loosely correlated | +0.54% |
Consumer Non Durables industry (528 stocks) | 26% Poorly correlated | +0.21% |